Novocure (NVCR) Reports Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC

Go back to Novocure (NVCR) Reports Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC

Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

April 13, 2021 7:30 AM EDT

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial

DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Following a routine review of the study by an independent data monitoring committee (DMC), Novocure was informed that the pre-specified... More